10-K: cbdMD, Inc. Reports Fiscal Year 2024 Results, Focuses on Cost Reduction and Strategic Growth

cbdMD, Inc. reports a reduced operating loss and improved adjusted EBITDA for fiscal year 2024, while navigating industry headwinds and focusing on strategic growth initiatives.

Summary

• cbdMD, Inc. reported a GAAP operating loss of $3.3 million for fiscal year 2024, an improvement of approximately $19.2 million compared to the previous year, which included a $13.2 million impairment loss.
• The company's non-GAAP adjusted EBITDA improved by $3.2 million year-over-year.
• Cash consumption was reduced from $4.9 million in fiscal 2023 to approximately $0.7 million in fiscal 2024.
• Net sales decreased by 19% to $19.5 million in fiscal 2024, primarily due to a decrease in total orders in both direct-to-consumer and wholesale divisions.
• E-commerce sales accounted for approximately 80% of total sales in fiscal 2024.
• The company launched a new line of nootropic functional mushrooms under the ATRx brand and expanded into the hemp-derived beverage category.
• The company is planning a new proposal to shareholders for the automatic conversion of Series A Preferred Stock to simplify its capital structure.
• The company faced short-term revenue impacts in the fourth quarter of fiscal 2024 due to email deliverability issues, digital marketing platform downtime, and international wholesale client regulatory registration requirements.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive signs of cost reduction and strategic diversification, the significant revenue decline and ongoing challenges raise concerns about the company's near-term prospects. The uncertainty around the capital structure and ability to repay debt also contribute to a neutral to slightly negative sentiment.

Positives

• The company has made significant improvements in reducing operating losses and cash consumption.
• The launch of new product lines, including functional mushrooms and hemp-derived beverages, diversifies the company's offerings.
• Improved SEO rankings are driving increased high-intent traffic.
• Wholesale demand is showing signs of recovery after regulatory hurdles.
• The company is actively working to simplify its capital structure, which could unlock additional equity value.

Negatives

• Net sales decreased by 19% in fiscal 2024, indicating ongoing challenges in revenue growth.
• The company experienced a sharp decline in email deliverability during the fourth quarter, impacting direct-to-consumer revenue.
• Ongoing downtime on digital marketing platforms tied to the CBD category continues to be a challenge.
• International wholesale clients faced new regulatory registration requirements, impacting sales for approximately 100 days.
• The company's Series A Preferred Stock continues to limit strategic investment and M&A opportunities.

Risks

• The company's ability to continue as a going concern is dependent on improving profitability and securing additional funding.
• The current capital structure limits the company's ability to make strategic acquisitions or attract new investors.
• The company's ability to repay outstanding notes upon their maturity in July 2025 is uncertain.
• The company faces risks related to the regulatory environment for dietary ingredients, including CBD.
• The company is subject to the continued listing standards of the NYSE American, and failure to comply may result in delisting.
• The company's recent negative growth rates may continue.
• The company relies on third-party suppliers and manufacturers, and disruptions in these relationships could harm operations.
• The company could be harmed by data loss or other security breaches.
• The company's future success depends on the continuing efforts of management and key employees.
• The company may be required to record future impairments of intangible or fixed assets.

Future Outlook

The company aims to simplify its capital structure, grow revenue in fiscal 2025, and expand into categories with fewer regulatory hurdles. Management anticipates recapturing most of the revenue lost in the September 2024 quarter during the first quarter of fiscal 2025.

Management Comments

• Management's efforts to drive shareholder value have been two fold: (i) deliver positive earnings through a combination of optimizing our product portfolio, rationalizing our cost structure, and growing revenue; and, (ii) simplifying our capital structure.
• We believe the combined market capitalization of both our common and Series A Preferred is being impacted due to our current capital structure.
• Our goal is to simplify our capital structure and we believe it will help unlock additional equity value and open up more strategic activity for the Company.
• We continue to believe in the long term benefits of hemp-derived cannabinoids, but see a longer-term horizon for federal regulatory clarity.
• At our core, we believe in natural health and wellness solutions and we believe in the benefits derived from functional mushrooms in addition to hemp.

Industry Context

The company is operating in a highly competitive dietary supplement market, particularly in the fragmented hemp-derived cannabinoid sector. The company is attempting to differentiate itself by focusing on hemp derived cannabinoids and seeking to identify new, emerging ingredients with functional efficacy for key consumer need states such as sleep, mood, focus and energy. The company is also facing competition in the functional mushroom market, which is a fast-growing segment of the overall dietary supplement market.

Comparison to Industry Standards

• The company's revenue decline of 19% in fiscal 2024 is worse than the overall growth seen in the broader dietary supplement market, but is consistent with the challenges faced by many CBD companies.
• The company's focus on cost reduction and improved EBITDA is a positive sign, but it needs to demonstrate sustainable revenue growth to compete effectively with larger, more established players in the industry.
• The company's move into functional mushrooms and hemp-derived beverages is a strategic attempt to diversify its product portfolio and reduce reliance on the highly regulated CBD market, similar to other companies in the space.
• The company's efforts to simplify its capital structure are crucial for attracting new investors and pursuing strategic opportunities, which is a common challenge for smaller companies with complex capital structures.

Legal Proceedings

• A purported collective and class action lawsuit filed in 2019 against cbdMD and certain competitors remains stayed until the FDA or Congress takes definitive action on the regulatory status of CBD.
• The company acquired the trademark of Majik Medicine, LLC, resolving all related legal claims.

Stakeholder Impact

• Shareholders face risks related to potential dilution, delisting, and the uncertainty of the company's ability to repay debt.
• Employees may be affected by ongoing cost-cutting measures and potential restructuring.
• Customers may benefit from new product offerings and improved customer experience.
• Suppliers and manufacturers may be impacted by changes in the company's sourcing and production strategies.
• Creditors face risks related to the company's ability to repay outstanding notes.

Next Steps

• The company is planning a new proposal to shareholders for the automatic conversion of Series A Preferred Stock.
• The company will continue to focus on expanding into categories that do not have as many regulatory and channel hurdles.
• The company will continue to pursue key wholesale accounts in several international markets.
• The company will continue to assess its product channel fit and work with retailers and distributors to further grow this channel.

Key Dates

Keywords

cbdMD, CBD, cannabidiol, hemp, functional mushrooms, ATRx, Paw CBD, dietary supplements, e-commerce, wholesale, capital structure, operating loss, EBITDA, marketing, regulatory, NYSE American